You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Patients

Asthma management focuses on helping patients to maintain control of their disease. Here are some patient profiles that highlight the type of patients our medicines are designed to support.

 

Discover Relvar Ellipta

Meet Amelia

Age: 34

Presentation:
Wheezing is starting to impact her life. She stays at home more and more, despite ICS maintenance therapy.

Discover Relvar Ellipta

Meet Leo

Age: 15

Presentation:
Night-time awakenings make it hard to focus on school. And when with friends, he often misses his second ICS dose.

Discover Relvar Ellipta

Could Relvar Ellipta (fluticasone furoate/vilanterol) help?

Prescribing information

Studies

Take a moment to explore how we know that Relvar Ellipta provides 24 hours of continuous efficacy. 1

 

The Salford Lung Study (SLS)

Clinical trials tell us a lot, but do they include the types of patient you see in everyday practice? This pragmatic trial of Relvar Ellipta (patients ≥ 18 years) vs. usual care did. 1

Find out about the SLS

Why move to a once-daily treatment

A once-daily treatment can make a huge difference to many patients. See how Relvar Ellipta demonstrated lasting effects over 24 hours. 2

See the data here

Your resources

Here you can watch expert perspectives, download valuable tools for use in your clinical practice and order from a range of free training devices.

Watch the experts

You’ll hear how our GSK medical experts tackle some of the key issues in asthma management and what this could mean for your patients.

View expert videos

Order the ACT pad

Assess the impact asthma is having on your patients’ lives by using the Asthma Control Test (ACT).

Order now

Free resources

Need an Ellipta training inhaler? Or simply looking for some patient resources on asthma? Then this is the place for you.

View all resources

Abbreviations

ACT, Asthma Control Test; ICS, inhaled corticosteroid

Indications:

Relvar Ellipta is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate: 3

  • Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting beta2-agonists
  • Patients already adequately controlled on both inhaled corticosteroid and long-acting beta2-agonist

References:

  1. Woodcock A, et al. Lancet. 2017; 390:2247–2255.
  2. Bernstein DI, et al. J Asthma. 2015; 52(10): 1073-1083.
  3. Relvar Ellipta SmPC, 2018.

Relvar Ellipta was developed in collaboration with